# David Goeddel

> David Goeddel is a Series B investor at The Column Group backing Biotechnology and Medical. See 16 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [The Column Group](https://shizune.co/investors/profile/the-column-group)
- Location: San Francisco, United States
- Total investments: 16
- Last investment: Oct 2022
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/david-goeddel-02806911

David Goeddel is a Series B investor at The Column Group in San Francisco focused on Biotechnology and Medical. Goeddel co-founded Tularik in November 1991, was Vice President of Research until 1996 and CEO from April 1996 - August 2004, when Tularik was acquired by Amgen. He served as Amgen's first Senior Scientific Vice President until May 2006. Prior to Tularik, he was the first scientist hired by Genentech, Inc. and from 1978 to 1993 servedin various positions, including Fellow, Staff Scientist and Director of Molecular Biology. His pioneering work in the fields of gene cloning and expression of human proteins has been the basis for five significant marketed therapeutics developed by Genentech, including human insulin, human growth hormone, interferon-alpha, interferon-gamma and tissue plasminogen activator. Goeddel has received numerous scientific awards including the Scheele Medal, the Eli Lilly Award in Biological Chemistry, the Inventor of the Year Award, the Jacob Heskel Gabbay Award, the Howley Prize for Arthritis Research and the Warren Alpert Foundation Prize. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 50% |
| Medical | 4 | 25% |
| Health Care | 4 | 25% |
| Therapeutics | 4 | 25% |
| Biopharma | 3 | 19% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 25% |
| Series A | 2 | 13% |
| Series C | 2 | 13% |
| Series D | 2 | 13% |
| Seed | 1 | 6% |

8 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hexagon Bio | Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics. Our proprietary platform combines data science and synthetic biology to discover and engineer drugs from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs. | $77.3M | Series B | Oct 11, 2022 |  |
| Hexagon Bio | Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics. Our proprietary platform combines data science and synthetic biology to discover and engineer drugs from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs. | $61M | Series B | Sep 22, 2021 |  |
| Hexagon Bio | Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics. Our proprietary platform combines data science and synthetic biology to discover and engineer drugs from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs. | $61M | Venture - Series Unknown | Sep 22, 2021 |  |
| Hexagon Bio | Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics. Our proprietary platform combines data science and synthetic biology to discover and engineer drugs from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs. | $47M | Series A | Sep 15, 2020 |  |
| Peloton Therapeutics | A peloton is a team of bicyclists who achieve great efficiency of motion through cooperative action. It is also the root of platoon, a nimble military unit with capabilities that exceed the sum of its component parts. Founded by Chairman of Biochemistry Steven L. McKnight of UT Southwestern Medical Center, Peloton Therapeutics represents a uniquecombination of innovative science, strong financial support from the Cancer Prevention Research Institute of Texas (CPRIT), and seasoned investors and management. Working in close collaboration with scientists at UT Southwestern, Peloton is advancing a promising discovery and development pipeline, comprised of several small molecule-based programs, each with a distinct target and mechanism of action. Peloton's vision is to become a major biotech company in Dallas with a passion for discovering and developing novel cancer drugs. | $150M | Series E | Feb 20, 2019 |  |
| Peloton Therapeutics | A peloton is a team of bicyclists who achieve great efficiency of motion through cooperative action. It is also the root of platoon, a nimble military unit with capabilities that exceed the sum of its component parts. Founded by Chairman of Biochemistry Steven L. McKnight of UT Southwestern Medical Center, Peloton Therapeutics represents a uniquecombination of innovative science, strong financial support from the Cancer Prevention Research Institute of Texas (CPRIT), and seasoned investors and management. Working in close collaboration with scientists at UT Southwestern, Peloton is advancing a promising discovery and development pipeline, comprised of several small molecule-based programs, each with a distinct target and mechanism of action. Peloton's vision is to become a major biotech company in Dallas with a passion for discovering and developing novel cancer drugs. | $52.4M | Series D | Sep 15, 2016 |  |
| NGM Biopharmaceuticals | NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic andcardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery. | $57.5M | Series D | Mar 23, 2015 |  |
| Flexus Biosciences | Flexus is a privately-held biopharmaceutical company focused on the creation, development, and commercialization of novel anti-cancer therapeutics through an innovative application of unexploited insights in immunology. Founded in 2013, Flexus is headquartered in San Carlos, California. | $38M | Series B | Dec 17, 2014 |  |
| Nurix Therapeutics | Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietaryDNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. | $25.1M | Series B | May 22, 2014 |  |
| Igenica | Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. They are the only biotherapeutic company that fully powers the ADC development spectrum from a clinically relevant approach to target and functional antibody discovery to ADC creation, acceleratingdevelopment and the delivery of effective therapies to patients.Founded in 2009, Igenica is led by a proven team of leaders that have demonstrated success in antibody drug discovery, clinical development and commercialization. Their leadership team has played a seminal role in six out of the 36 currently approved antibody therapeutic products.Based in Burlingame, Calif., they are well-funded by a premier team of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures. | $14M | Series C | Jan 28, 2014 |  |

10 of 16 investments shown.

## Co-investors
- [Nextech Invest](https://shizune.co/investors/profile/nextech-invest) — VC Fund, 5 deals together
- [Third Rock Ventures](https://shizune.co/investors/profile/third-rock-ventures) — VC Fund, 5 deals together
- [8VC](https://shizune.co/investors/profile/8vc) — VC Fund, 4 deals together
- [Two Sigma Ventures](https://shizune.co/investors/profile/two-sigma-ventures) — VC Fund, 4 deals together
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 3 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 2 deals together

## About The Column Group

VC Fund · San Francisco, United States

The Column Group is a venture capital firm dedicated to creating the next generation of biotechnology companies. They manage over $4 billion in assets and focus on building companies with groundbreaking scientific platforms that have the potential to deliver significant new therapies for unmet medical needs. TCG takes a long-term approach, aimingto develop companies capable of generating multiple product opportunities rather than focusing on quick exits.

5 contacts available at The Column Group.

| Name | Title | Profile |
| --- | --- | --- |
| David Goeddel | Managing Partner | https://shizune.co/investors/profile/david-v-goeddel |
| Jeff Goater | Venture Partner | https://shizune.co/investors/profile/dinah-sah-2 |
| Joseph Goldstein | Science Partner | https://shizune.co/investors/profile/joseph-l-goldstein |
| Millie Ray | Partner | https://shizune.co/investors/profile/millie-ray |
| Peter Svennilson | Managing Partner and Founder | https://shizune.co/investors/profile/peter-svennilson |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does David Goeddel invest in?

David Goeddel invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did David Goeddel last invest?

The most recent investment recorded for David Goeddel closed in Oct 2022. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co